Last edition
News about "Memorial Sloan Kettering Cancer Center"
AbbVie Receives FDA Approval for EPKINLY Combo in Relapsed/Refractory Follicular Lymphoma
AbbVie has secured FDA approval for EPKINLY in combination with rituximab and lenalidomide (EPKINLY + R2), marking the first bispecific antibody combo therapy available for patients with relapsed or refractory follicular lymphoma after at least one prior systemic treatment.
Memorial Sloan Kettering Cancer Center | 19/11/2025 | By Dineshwori | 150
Actinium Pharmaceuticals has entered a research collaboration with Memorial Sloan Kettering Cancer Center to expand Actimab-A’s mutation-agnostic mechanism in AML through targeted therapy combinations and patient-derived models.
Memorial Sloan Kettering Cancer Center | 20/03/2025 | By Aishwarya | 197
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy